Dimeric l-Dopa Derivatives as Potential Prodrugs
Section snippets
Acknowledgements
This work was supported by the Ministero della Università e della Ricerca Scientifica e Tecnologica (Progetto Nazionale Tecnologie Farmaceutiche). The authors thank Prof. M. Cardellini for his collaboration and Mr. Domenico Rapposelli for his technical assistance.
References (14)
- et al.
Bioorg. Med. Chem. Lett.
(2000) - et al.
Eur. J. Pharm. Sci.
(1996) - et al.
Eur. J. Med. Chem.
(1998) - et al.
Eur. J. Med. Chem.
(1994) - et al.
Drugs Today
(1999) - et al.
J. Med. Chem.
(1977) - et al.
J. Pharm. Pharmacol.
(1987)
Cited by (33)
Solid lipid nanoparticles for efficient delivery of capsaicin-rich extract: Potential neuroprotective effects in Parkinson's disease
2024, Journal of Drug Delivery Science and TechnologyDevelopment of Prodrugs for Treatment of Parkinson‘s Disease: New Inorganic Scaffolds for Blood–Brain Barrier Permeation
2022, Journal of Pharmaceutical SciencesCitation Excerpt :Dimeric L-DOPA acetylated derivatives (XXXVIII): are one of the few examples of dimeric prodrugs of L-DOPA. Their lipophilicity and the rates of enzymatic and chemical hydrolysis were found to be in the suitable range for PD treatment.96 Further studies on oral bioavailability have not been published yet.
L-dopa co-drugs in nanostructured lipid carriers: A comparative study
2017, Materials Science and Engineering CCitation Excerpt :These multifunctional co-drugs could represent useful dopaminergic agents devoid of the pro-oxidant effects associated with the presence of the catechol moiety [13]. Finally, PDD, prepared by coupling reaction between 3,4-diacetyloxy-l-phenylalanine methyl ester hydrochloride with hexanedioyl dichloride, showed chemical stability in aqueous, acid, and physiological solutions [14]. However, all LD co-drugs, reported in this study, showed poor water solubility.
Design, synthesis and biological evaluation of peptide derivatives of l-dopa as anti-parkinsonian agents
2013, Bioorganic and Medicinal Chemistry LettersPreparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug
2011, International Journal of PharmaceuticsCitation Excerpt :The current chemotherapy is essentially symptomatic using exogenous l-Dopa (LD), the direct precursor of DA, as drug (Blandini and Greenamyre, 1999; Andersen, 2004; Fahn, 2006). LD administration is however associated with three important problems: (i) LD metabolism generates a variety of cytotoxic reactive oxygen species (ROS) that contribute to the progression of the disease; (ii) LD has a poor bioavailability in the CNS; (iii) during chronic treatment, patients become sensitive to LD plasma level fluctuations (Dauer and Przedborski, 2003; Bindoli et al., 1992; Di Stefano et al., 2001). In order to overcome these problems, a multifunctional prodrug (LD–LA, Fig. 1) containing LD and natural lipoic acid moiety (LA) has been recently synthesized (Di Stefano et al., 2006).
Simultaneous determination of l-dopa and its prodrug (S)-4-(2-acetamido-3-ethoxy-3-oxopropyl)-1,2-phenylene diacetate in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study
2010, Journal of Pharmaceutical and Biomedical Analysis